Showing 4401-4410 of 6808 results for "".
- FDA Approves Odomzo for Locally Advanced BCChttps://practicaldermatology.com/news/fda-approves-odomzo-sonidegib-for-locally-advanced-bcc/2458903/The FDA approved Novartis’ Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radi
- Brickell Biotech Appoints Patricia Walker, MD, PhD as President and CSOhttps://practicaldermatology.com/news/brickell-biotech-appoints-patricia-walker-md-phd-as-president-and-cso/2458912/Patricia Walker, MD, PhD has joined Brickell Biotech, Inc. as President and Chief Scientific Officer. Dr. Walker, a board-certified dermatologist specializing in medical and aesthetic dermatology, most recently served as the Chief Medical Officer for Kythera Biopharmaceuticals, Inc. Over
- SCOTUS Upholds Affordable Care Act in King v. Burwell Ruling; AADA and AMA Issue Statementshttps://practicaldermatology.com/news/scotus-upholds-affordable-care-act-in-king-v-burwell-ruling-aada-and-ama-issue-statements/2458920/In a 6-3 ruling in King v. Burwell, the US Supreme Court upheld tax subsidies for the Affordable Care Act. Steven J. Stack, MD, President of the American Medical Association release a statement on the decision, saying “The American Medical Association (AMA) is relieved that today&rs
- MELA Sciences Acquires XTRAC and VTRAC Businesses From PhotoMedex, Inc.https://practicaldermatology.com/news/mela-sciences-acquires-xtrac-and-vtrac-businesses-from-photomedex-inc/2458923/MELA Sciences, Inc. has signed and completed the purchase of the XTRAC and VTRAC Dermatology business from PhotoMedex, Inc. for $42.5 million in cash and the assumption of certain business-related liabilities. The purchase price includes all of the accounts receivable, inventory an
- BTL Vanquish FDA Cleared for Circumferential Reduction of Abdomen Areahttps://practicaldermatology.com/news/btl-vanquish-fda-cleared-for-circumferential-reduction-of-abdomen-area/2458926/BTL Industries received FDA clearance of its BTL Vanquish device for circumferential reduction of the abdomen area. BTL Vanquish uses a panel array that emits selective RF energy with the largest spot size in the industry t
- FDA Grants Breakthrough Therapy Designation for Actemra in Systemic Sclerosishttps://practicaldermatology.com/news/fda-grants-breakthrough-therapy-designation-for-actemra-in-systemic-sclerosis/2458929/Genentech, a member of the Roche Group, was granted FDA Breakthrough Therapy Designation status for Actemra® (tocilizumab) for systemic sclerosis, also known as scleroderma. This designation is intended to expedite the development and review of medicines with early signals of poten
- NIH Funding Often Does Not Match Disease Burden for Dermatologic Conditionshttps://practicaldermatology.com/news/nih-funding-often-does-not-match-disease-burden-for-dermatologic-conditions/2458930/A new analysis of funding prioritization by the National Institutes of Health for skin disease offers a glimpse of cutaneous skin disease on a national level, with some disease states being possibly underfunded. Examining the relationship between dermatologic research funding and skin disease bur
- InMed Pharmaceuticals Files Provisional Patent for Novel Compounds to Treat Epidermolysis Bullosa Simplexhttps://practicaldermatology.com/news/inmed-pharmaceuticals-files-provisional-patent-for-novel-compounds-to-treat-epidermolysis-bullosa-simplex/2458939/InMed Pharmaceuticals Inc. filed a provisional patent application with the United States Patent and Trademark Office relating to the treatment of Epidermolysis Bullosa Simplex (EBS) using novel formulations of natural cannabinoid compounds developed by InMed. Dr. Sazzad Hossain, InMed Pha
- arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditionshttps://practicaldermatology.com/news/argen-x-and-leo-pharma-enter-into-alliance-to-develop-antibody-based-treatments-for-skin-conditions/2458940/arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, and LEO Pharma entered into an alliance in which they will collaborate to develop antibody-based solutions for the treatment
- The American Academy of Dermatology Elects New Officers and Board Membershttps://practicaldermatology.com/news/the-american-academy-of-dermatology-elects-new-officers-and-board-members/2458941/The American Academy of Dermatology (AAD) announced the results of its annual election. The newly elected officers and board members will lead the AAD, which represents more than 19,000 physicians. These officers and board members also will hold the same positions for the American Academy of Derm